APRE
NASDAQAprea Therapeutics Inc.
News · 26 weeks49+150%
2026-03-012026-08-23
Mix1890d
- Insider8(44%)
- Other5(28%)
- SEC Filings4(22%)
- Leadership1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
- SECSEC Form 10-Q filed by Aprea Therapeutics Inc.10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Announces Second Quarter 2026 Financial ResultsEnrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051, including partial responses and disease stabilization, with a manageable tolerability profile $41.2 million in cash and cash equivalents as of June 30, 2026 DOYLESTOWN, Pa., Aug. 12, 2026 (GLOBE NE
- PRLipocine Appoints Michael J. Grissinger to Board of DirectorsSALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026. "We are pleased to welcome Mike Grissinger to our Board of Directors," said Dana Ono, Ph.D., Chairman of the Board of Lipocine. "Mike brings extensive experience leading pharmaceutical licensing, corporate development, and mergers and acquisitions. As Lipocine works to advance the pipeline and pursue partnerships for
- PRAprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051Enrollment in ACESOT-1051 is accelerating as the Company advances dose escalation and amasses the clinical data needed to inform dose selection and subsequent developmentAprea plans to advance APR-1051 in uterine serous carcinoma (USC) and Cyclin E–overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head and neck cancer and colorectal cancer, utilizing dose levels that have shown single-agent
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRNext-Generation DNA Repair Therapies Open New Frontiers in OncologyAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Li
- INSIDERDirector Grissinger Michael was granted 3,135 shares, increasing direct ownership by 109% to 6,024 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Gruia Gabriela was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Peters Richard was granted 3,135 shares, increasing direct ownership by 101% to 6,254 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Henneman John B Iii was granted 3,135 shares, increasing direct ownership by 31% to 13,364 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Bizzari Jean-Pierre was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Duey Marc was granted 3,135 shares, increasing direct ownership by 1% to 259,290 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Pamukcu Rifat was granted 3,135 shares, increasing direct ownership by 58% to 8,581 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERDirector Seizinger Bernd R. was granted 3,135 shares, increasing direct ownership by 7% to 48,910 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid TumorsPresentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across cohortsPatient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster "Early results
- SECSEC Form SCHEDULE 13G filed by Aprea Therapeutics Inc.SCHEDULE 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
- SECSEC Form 424B7 filed by Aprea Therapeutics Inc.424B7 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form 10-Q filed by Aprea Therapeutics Inc.10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateOversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026$46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028 DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of
- SECSEC Form DEFA14A filed by Aprea Therapeutics Inc.DEFA14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form DEF 14A filed by Aprea Therapeutics Inc.DEF 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
APRE FAQ
7 questionsWhat does Aprea Therapeutics Inc. do?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53...Where does APRE stock trade?
Aprea Therapeutics Inc. (APRE) is listed on NASDAQ.What sector and industry is APRE in?
Aprea Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aprea Therapeutics Inc. go public?
Aprea Therapeutics Inc. (APRE) completed its IPO in 2019.What are analysts saying about APRE?
Aprea Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from JP Morgan: Underweight on 2021-08-20. Recent price targets range from $300.00 to $500.00.What companies are similar to APRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare APRE side-by-side with any of them on Quantisnow.How can I track APRE on Quantisnow?
Quantisnow aggregates Aprea Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APRE to receive live email and push alerts on every new disclosure.